You are here: Industry Insights > Bausch Health

News List

Yehia Hashad Will Join Bausch + Lomb as EVP of R&D and CMO FirstWordPharma
January 21, 2022
Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") has announced that Dr. Yehia Hashad will join Bausch + Lomb Corporation ("Bausch + Lomb") as executive vice president...
Glenmark, Bausch Health partner to commercialise RYALTRIS nasal spray in Canada expresspharma
March 23, 2021
RYALTRIS is currently under review by Health Canada with a proposed indication for the treatment of seasonal allergic rhinitis in adults and children over 12 years of age.
Bausch Health's DEXAVEN (Dexamethasone Phosphate) Receives New Indication In Poland To Treat Patients With SARS-CoV-2 (COVID-19) prnewswire
December 31, 2020
Bausch Health Companies Inc., announced that the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products in Poland has granted an additional new indication for DEXAVEN (dexamethasone phosphate) solution for injection ...
Bausch Health to acquire ophthalmology assets of Allegro pharmaceutical-technology
September 23, 2020
Bausch Health has signed an agreement to acquire an option to buy biopharmaceutical company Allegro Ophthalmics’ ophthalmological assets.
Bausch Health Initiates VIRAZOLE Study in Patients with COVID-19 americanpharmaceuticalreview
April 15, 2020
Bausch Health has initiated a clinical trial program in Canada evaluating an investigational use of VIRAZOLE® (Ribavirin for Inhalation Solution, USP) in combination ...
Bausch Health is far from the LeBron James in eye care, so don't compare it to Alcon fiercepharma
April 23, 2019
After Novartis eye care spinoff Alcon made a successful debut on the Swiss Exchange earlier this month, some analysts used it as an argument to make a bullish case for Bausch Health. But one analyst disagrees.
‘Organic’ growth and ‘pivoting’ at Bausch Health? One analyst begs to disagree fiercepharma
February 24, 2019
One key word that was repeated over and over on Bausch Health’s fourth-quarter earnings call was “organic,” as management tried to convince investors that it is pivoting away from some old bad habits. But one analyst wasn’t buying it.
Bausch Health Announces Launch Of Private Offering Of Senior Secured Notes And Add-On Unsecured Notes firstwordpharma
February 24, 2019
The Secured Notes will be guaranteed by BHA and each of the Company's other subsidiaries that are guarantors under the Company's credit agreement and existing senior notes and will be secured on a first priority basis by liens on the assets that secure th
Bausch Health Commences Cash Tender Offers And Consent Solicitation For Up To $1,250,000,000 Aggregate Purchase Price firstwordpharma
February 24, 2019
Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health," the "Company" or the "Offeror") announced today that it has commenced cash tender oﬀers (collectively, the "Tender Oﬀers," and each offer to purchase a series of notes individually, a "Tender
Bausch Health Acquires Eton’s M-100 Investigational Eye Drop americanpharmaceuticalreview
February 20, 2019
Bausch Health Companies and Bausch + Lomb, its wholly owned subsidiary and a leading global eye health company, and Eton Pharmaceuticals announced a subsidiary of Bausch Health has acquired the U.S. rights to Eton Pharmaceuticals' EM-100.....

Previous page 1 2 Next page